Kenvue Inc

Kenvue's capital structure is characterized by a debt-to-equity ratio of 0.81, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.99 and negative net cash after subtracting total debt. Free cash flow is negative at -$91 million, while operating cash flow stands at $287 million, suggesting operational cash generation is insufficient to cover capital expenditures. Profitability metrics show a return on equity (ROE) of 2.79% and a return on assets (ROA) of 1.08%, both below the industry median for Personal Products. The company's gross margin is 57.6%, calculated from a gross profit of $2.24 billion on $3.89 billion in revenue, but operating margin is only 14.1%, reflecting high operating expenses. Geographically, Kenvue's revenue is concentrated in North America, which accounts for 62% of total revenue, followed by Europe (23%) and the Asia-Pacific region (15%). The company's segmental breakdown includes OTC Health, which contributes 78% of revenue, and Personal Care, which accounts for 22%. Looking ahead, Kenvue's revenue is projected to grow by 3.5% in the current fiscal year and 4.2% in the next, driven by new product launches and market expansion. However, the company's high price-to-earnings ratio of 115.13 and price-to-book ratio of 3.21 suggest that the market is pricing in significant future growth expectations. Risk factors include liquidity constraints and the potential for dilution, though the latter is currently assessed as low. The company has not issued additional shares recently, and no dilutive events are currently flagged in the risk assessment. However, the negative free cash flow and high debt levels could limit flexibility in the event of a downturn. Recent events include a 10-K filing that disclosed ongoing supply chain challenges and a Q4 earnings call where management outlined plans to streamline operations and reduce costs. Analysts have issued a mean price target of $19.78, with a median of $19.00, and a mean recommendation of 3.00 (Hold).